TP53 and cancer: Studies on esophageal cancer models demonstrate that TPP1 exerts its effects through the ATM/ATR-p53 signaling pathway, with two notable impacts: it decreases the sensitivity of cancer cells to cisplatin and reduces DNA damage, possibly by stabilizing telomere structure or enhancing DNA repair mechanisms [92].